Suchergebnisse
Suchergebnisse:
Vor 8 Stunden · Moderna, Inc. und die Mitsubishi Tanabe Pharma Corporation gaben bekannt, dass die beiden Unternehmen eine gemeinsame Vereinbarung über die gemeinsame Vermarktung des mRNA-Impfstoffportfolios von Moderna für die Atemwege in Japan getroffen haben, einschließlich des COVID-19-Impfstoffs Spikevax® von Moderna. Im Rahmen der Vereinbarung wird Moderna die Herstellung, den Verkauf, die ...
Vor 8 Stunden · WASHINGTON (dpa-AFX) - Moderna Inc. (MRNA) and Mitsubishi Tanabe Pharma Corporation have partnered to jointly promote Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's
Vor 6 Stunden · Moderna Inc. ( MRNA) and Mitsubishi Tanabe Pharma Corporation have partnered to jointly promote Moderna's mRNA respiratory vaccine portfolio in Japan, including Moderna's COVID-19 vaccine, Spikevax. As per the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines.
Vor 8 Stunden · Moderna, Inc. en Mitsubishi Tanabe Pharma Corporation hebben aangekondigd dat de bedrijven een gezamenlijke overeenkomst zijn aangegaan voor de co-promotie van Moderna's mRNA respiratoire vaccinportfolio in Japan, inclusief Moderna's COVID-19 vaccin, Spikevax®. Volgens de overeenkomst zal Moderna zich bezighouden met de productie, verkoop, medische voorlichting en distributie van haar mRNA ...
Vor 8 Stunden · Moderna et Mitsubishi Tanabe Pharma Corporation concluent un accord commun pour promouvoir le portefeuille de vaccins respiratoires à ARNm de Moderna au Japon, y compris les vaccins Covid-19. CI ...
Vor 8 Stunden · Moderna, Inc. e Mitsubishi Tanabe Pharma Corporation hanno annunciato di aver stipulato un accordo congiunto per la co-promozione del portafoglio di vaccini respiratori mRNA di Moderna in Giappone, compreso il vaccino COVID-19 di Moderna, Spikevax®. In base all'accordo, Moderna si occuperà della produzione, della vendita, della formazione medica e della distribuzione dei suoi vaccini ...
Vor 8 Stunden · Clinical Sites and Site Investigators, by Enrolment Akihiro Miyasaki 27, Masanori Isobe 28, Yoshitaka Suda 29, Kazuo Kitagawa 30, Kazuyuki Nagatsuka 11, Shuta Toru 31, Makoto Katsuno 32, Nobuyuki ...
